The law firms and barristers who defended former Dick Smith directors in sprawling litigation over the failure of the electronics retailer earned close to $68 million in fees, a court has heard.
Rio Tinto will face a penalty in proceedings brought by the Australian Securities and Investments Commission alleging the mining giant misled shareholders about the resources of a Mozambique mining company it acquired for $5.8 billion in 2011 and later offloaded for $70 million.
A group of nurses have dropped their lawsuit against Monash Health alleging the hospital provider threatened to take adverse action against them for failing to get vaccinated against COVID-19.
A Federal Court judge has reconsidered her plan to dispense with a hearing to weigh a $1.55 million settlement of two class actions that allege supermarket chain Romeo’s underpaid hundreds of workers at stores in NSW and South Australia.
The Australian Securities and Investments Commission has dropped its investigation into Nuix’s financial statements in the lead-up to its 2020 public float, but will continue to probe the troubled tech company’s statements in the period since the initial public offering.
Macpherson Kelley will head to an eleventh-hour mediation in a negligence case over the execution of a 10-year service station lease agreement with Shell, after the court heard settlement talks were well progressed.
AMP has expressed optimism that it will be able to reach a settlement with DST Bluedoor in a $35.5 million lawsuit accusing it of poaching 11 DST employees after licensing the software company’s online platform.
A court has ordered the winding up of investment manager PE Capital Funds Management, whose responsible entity Endeavour Securities has connections to collapsed financial services company Linchpin Capital.
Forum Finance director Vince Tesoriero has lost a battle to stop receivers from selling luxury properties in which he and Bill Papas hold a stake pending the outcome of Westpac’s fraud case against him.
Bristol-Myers Squibb has agreed to open up its subsidised treatment program for stage IV melanoma patients to individuals who have been treated with drugs made by its competitors to settle a misuse of market power lawsuit brought by rival Merck Sharpe & Dohme.